Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

zirconium Zr 89-cetuximab

A radioimmunoconjugate comprised of the recombinant chimeric monoclonal antibody cetuximab labeled with the radioisotope zirconium Z 89 (Zr 89) with radioisotopic activity and potential imaging use. The antibody moiety of zirconium Zr 89-cetuximab binds to the extracellular domain of the epidermal growth factor receptor (EGFR). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), allowing the imaging and quantification of EGFR-expressing tumor cells. EGFR is a tyrosine kinase that may be overexpressed on the cell surfaces of various tumor cell types.
Synonym:cetuximab-zirconium-89
zirconium Zr 89 cetuximab
zirconium-89-labeled cetuximab
Abbreviation:cetuximab-Zr-89
Search NCI's Drug Dictionary